Selected research
Industry Research
GABA Receptor Agonist Drug Industry Research Report 2026
Market perspective
The global GABA Receptor Agonist Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for GABA Receptor Agonist Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for GABA Receptor Agonist Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for GABA Receptor Agonist Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of GABA Receptor Agonist Drug include Novartis, Eli Lilly and Company, Pfizer, GlaxoSmithKline, AstraZeneca, XenoPort, VIVUS, sanofi-aventis and OVATION Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global GABA Receptor Agonist Drug market in terms of revenue (US$ million) and, where applicable, sales volume (k units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
GABA Receptor Agonist Drug Market by Company
Novartis
Eli Lilly and Company
Pfizer
GlaxoSmithKline
AstraZeneca
XenoPort
VIVUS
sanofi-aventis
OVATION Pharmaceuticals
Osmotica Pharmaceutical
NovaDel Pharma
H.LundBeck, Merck and Co
Elan Corporation
Biocodex
Athena Drug Delivery Solutions
Advicenne
GABA Receptor Agonist Drug Segment by Type
Baclofen
Bamaluzole
Phenibut
Gaboxadol
Klonopin (clonazepam)
Tiagbine
GABA Receptor Agonist Drug Segment by Application
Alzheimer
Epilepsy and Seizure
Obesity and Alcoholism
Anxiety and Sleep Disorders
Psychiatric Disorders and Depression
Attention Deficit Hyperactivity Disorder (ADHD)
GABA Receptor Agonist Drug Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GABA Receptor Agonist Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of GABA Receptor Agonist Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GABA Receptor Agonist Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of GABA Receptor Agonist Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of GABA Receptor Agonist Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of GABA Receptor Agonist Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Baclofen
- Bamaluzole
- Phenibut
- Gaboxadol
- Klonopin (clonazepam)
- Tiagbine
Applications
- Alzheimer
- Epilepsy and Seizure
- Obesity and Alcoholism
- Anxiety and Sleep Disorders
- Psychiatric Disorders and Depression
- Attention Deficit Hyperactivity Disorder (ADHD)
Companies covered
- Novartis
- Eli Lilly and Company
- Pfizer
- GlaxoSmithKline
- AstraZeneca
- XenoPort
- VIVUS
- sanofi-aventis
- OVATION Pharmaceuticals
- Osmotica Pharmaceutical
- NovaDel Pharma
- H.LundBeck, Merck and Co
- Elan Corporation
- Biocodex
- Athena Drug Delivery Solutions
- Advicenne
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global GABA Receptor Agonist Drug Market Size (2021-2032)
- 2.2.2 Global GABA Receptor Agonist Drug Sales (2021-2032)
- 2.2.3 Global GABA Receptor Agonist Drug Market Average Price (2021-2032)
- 2.3 GABA Receptor Agonist Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Baclofen
- 2.3.3 Bamaluzole
- 2.3.4 Phenibut
- 2.3.5 Gaboxadol
- 2.3.6 Klonopin (clonazepam)
- 2.3.7 Tiagbine
- 2.4 GABA Receptor Agonist Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Alzheimer
- 2.4.3 Epilepsy and Seizure
- 2.4.4 Obesity and Alcoholism
- 2.4.5 Anxiety and Sleep Disorders
- 2.4.6 Psychiatric Disorders and Depression
- 2.4.7 Attention Deficit Hyperactivity Disorder (ADHD)
3 Market Competitive Landscape by Manufacturers
- 3.1 Global GABA Receptor Agonist Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global GABA Receptor Agonist Drug Sales (k units) of Manufacturers (2021-2026)
- 3.3 Global GABA Receptor Agonist Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global GABA Receptor Agonist Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global GABA Receptor Agonist Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of GABA Receptor Agonist Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of GABA Receptor Agonist Drug, Product Type & Application
- 3.8 Global Manufacturers of GABA Receptor Agonist Drug, Established Date
- 3.9 Global GABA Receptor Agonist Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Novartis
- 4.1.1 Novartis Company Information
- 4.1.2 Novartis Business Overview
- 4.1.3 Novartis GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Novartis GABA Receptor Agonist Drug Product Portfolio
- 4.1.5 Novartis Recent Developments
- 4.2 Eli Lilly and Company
- 4.2.1 Eli Lilly and Company Company Information
- 4.2.2 Eli Lilly and Company Business Overview
- 4.2.3 Eli Lilly and Company GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Eli Lilly and Company GABA Receptor Agonist Drug Product Portfolio
- 4.2.5 Eli Lilly and Company Recent Developments
- 4.3 Pfizer
- 4.3.1 Pfizer Company Information
- 4.3.2 Pfizer Business Overview
- 4.3.3 Pfizer GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Pfizer GABA Receptor Agonist Drug Product Portfolio
- 4.3.5 Pfizer Recent Developments
- 4.4 GlaxoSmithKline
- 4.4.1 GlaxoSmithKline Company Information
- 4.4.2 GlaxoSmithKline Business Overview
- 4.4.3 GlaxoSmithKline GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 GlaxoSmithKline GABA Receptor Agonist Drug Product Portfolio
- 4.4.5 GlaxoSmithKline Recent Developments
- 4.5 AstraZeneca
- 4.5.1 AstraZeneca Company Information
- 4.5.2 AstraZeneca Business Overview
- 4.5.3 AstraZeneca GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 AstraZeneca GABA Receptor Agonist Drug Product Portfolio
- 4.5.5 AstraZeneca Recent Developments
- 4.6 XenoPort
- 4.6.1 XenoPort Company Information
- 4.6.2 XenoPort Business Overview
- 4.6.3 XenoPort GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 XenoPort GABA Receptor Agonist Drug Product Portfolio
- 4.6.5 XenoPort Recent Developments
- 4.7 VIVUS
- 4.7.1 VIVUS Company Information
- 4.7.2 VIVUS Business Overview
- 4.7.3 VIVUS GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 VIVUS GABA Receptor Agonist Drug Product Portfolio
- 4.7.5 VIVUS Recent Developments
- 4.8 sanofi-aventis
- 4.8.1 sanofi-aventis Company Information
- 4.8.2 sanofi-aventis Business Overview
- 4.8.3 sanofi-aventis GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 sanofi-aventis GABA Receptor Agonist Drug Product Portfolio
- 4.8.5 sanofi-aventis Recent Developments
- 4.9 OVATION Pharmaceuticals
- 4.9.1 OVATION Pharmaceuticals Company Information
- 4.9.2 OVATION Pharmaceuticals Business Overview
- 4.9.3 OVATION Pharmaceuticals GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.9.4 OVATION Pharmaceuticals GABA Receptor Agonist Drug Product Portfolio
- 4.9.5 OVATION Pharmaceuticals Recent Developments
- 4.10 Osmotica Pharmaceutical
- 4.10.1 Osmotica Pharmaceutical Company Information
- 4.10.2 Osmotica Pharmaceutical Business Overview
- 4.10.3 Osmotica Pharmaceutical GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.10.4 Osmotica Pharmaceutical GABA Receptor Agonist Drug Product Portfolio
- 4.10.5 Osmotica Pharmaceutical Recent Developments
- 4.11 NovaDel Pharma
- 4.11.1 NovaDel Pharma Company Information
- 4.11.2 NovaDel Pharma Business Overview
- 4.11.3 NovaDel Pharma GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.11.4 NovaDel Pharma GABA Receptor Agonist Drug Product Portfolio
- 4.11.5 NovaDel Pharma Recent Developments
- 4.12 H.LundBeck, Merck and Co
- 4.12.1 H.LundBeck, Merck and Co Company Information
- 4.12.2 H.LundBeck, Merck and Co Business Overview
- 4.12.3 H.LundBeck, Merck and Co GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.12.4 H.LundBeck, Merck and Co GABA Receptor Agonist Drug Product Portfolio
- 4.12.5 H.LundBeck, Merck and Co Recent Developments
- 4.13 Elan Corporation
- 4.13.1 Elan Corporation Company Information
- 4.13.2 Elan Corporation Business Overview
- 4.13.3 Elan Corporation GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.13.4 Elan Corporation GABA Receptor Agonist Drug Product Portfolio
- 4.13.5 Elan Corporation Recent Developments
- 4.14 Biocodex
- 4.14.1 Biocodex Company Information
- 4.14.2 Biocodex Business Overview
- 4.14.3 Biocodex GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.14.4 Biocodex GABA Receptor Agonist Drug Product Portfolio
- 4.14.5 Biocodex Recent Developments
- 4.15 Athena Drug Delivery Solutions
- 4.15.1 Athena Drug Delivery Solutions Company Information
- 4.15.2 Athena Drug Delivery Solutions Business Overview
- 4.15.3 Athena Drug Delivery Solutions GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.15.4 Athena Drug Delivery Solutions GABA Receptor Agonist Drug Product Portfolio
- 4.15.5 Athena Drug Delivery Solutions Recent Developments
- 4.16 Advicenne
- 4.16.1 Advicenne Company Information
- 4.16.2 Advicenne Business Overview
- 4.16.3 Advicenne GABA Receptor Agonist Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.16.4 Advicenne GABA Receptor Agonist Drug Product Portfolio
- 4.16.5 Advicenne Recent Developments
5 Global GABA Receptor Agonist Drug Market Scenario by Region
- 5.1 Global GABA Receptor Agonist Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global GABA Receptor Agonist Drug Sales by Region: 2021-2032
- 5.2.1 Global GABA Receptor Agonist Drug Sales by Region: 2021-2026
- 5.2.2 Global GABA Receptor Agonist Drug Sales by Region: 2027-2032
- 5.3 Global GABA Receptor Agonist Drug Revenue by Region: 2021-2032
- 5.3.1 Global GABA Receptor Agonist Drug Revenue by Region: 2021-2026
- 5.3.2 Global GABA Receptor Agonist Drug Revenue by Region: 2027-2032
- 5.4 North America GABA Receptor Agonist Drug Market Facts & Figures by Country
- 5.4.1 North America GABA Receptor Agonist Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America GABA Receptor Agonist Drug Sales by Country (2021-2032)
- 5.4.3 North America GABA Receptor Agonist Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe GABA Receptor Agonist Drug Market Facts & Figures by Country
- 5.5.1 Europe GABA Receptor Agonist Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe GABA Receptor Agonist Drug Sales by Country (2021-2032)
- 5.5.3 Europe GABA Receptor Agonist Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific GABA Receptor Agonist Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific GABA Receptor Agonist Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific GABA Receptor Agonist Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific GABA Receptor Agonist Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America GABA Receptor Agonist Drug Market Facts & Figures by Country
- 5.7.1 South America GABA Receptor Agonist Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America GABA Receptor Agonist Drug Sales by Country (2021-2032)
- 5.7.3 South America GABA Receptor Agonist Drug Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa GABA Receptor Agonist Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa GABA Receptor Agonist Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa GABA Receptor Agonist Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa GABA Receptor Agonist Drug Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global GABA Receptor Agonist Drug Sales by Type (2021-2032)
- 6.1.1 Global GABA Receptor Agonist Drug Sales by Type (2021-2032) & (k units)
- 6.1.2 Global GABA Receptor Agonist Drug Sales Market Share by Type (2021-2032)
- 6.2 Global GABA Receptor Agonist Drug Revenue by Type (2021-2032)
- 6.2.1 Global GABA Receptor Agonist Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global GABA Receptor Agonist Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global GABA Receptor Agonist Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global GABA Receptor Agonist Drug Sales by Application (2021-2032)
- 7.1.1 Global GABA Receptor Agonist Drug Sales by Application (2021-2032) & (k units)
- 7.1.2 Global GABA Receptor Agonist Drug Sales Market Share by Application (2021-2032)
- 7.2 Global GABA Receptor Agonist Drug Revenue by Application (2021-2032)
- 7.2.1 Global GABA Receptor Agonist Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global GABA Receptor Agonist Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global GABA Receptor Agonist Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 GABA Receptor Agonist Drug Value Chain Analysis
- 8.1.1 GABA Receptor Agonist Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 GABA Receptor Agonist Drug Production Mode & Process
- 8.2 GABA Receptor Agonist Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 GABA Receptor Agonist Drug Distributors
- 8.2.3 GABA Receptor Agonist Drug Customers
9 Global GABA Receptor Agonist Drug Analyzing Market Dynamics
- 9.1 GABA Receptor Agonist Drug Industry Trends
- 9.2 GABA Receptor Agonist Drug Industry Drivers
- 9.3 GABA Receptor Agonist Drug Industry Opportunities and Challenges
- 9.4 GABA Receptor Agonist Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst